MON-FRI8AM - 5PMCALL US+254 718 473 446

Prevention & Survivorship

ICI is committed to promoting prevention science and integrating evidence-based prevention strategies into oncology practice. ICI’s prevention goals are to promote clinical, behavioral, and translational research, and education and training in cancer prevention and control. ICI is also committed to survivors of cancer, who require long-term surveillance, risk assessment, and prevention services. ICI mainly engages in the following advocacy activities:

Tobacco Cessation & Control

ICI has outlined a far-reaching agenda aimed at promoting worldwide reduction and ultimate elimination of tobacco-related disease through discouraging the use of tobacco products and exposure to secondhand smoke (SHS). In this pursuit, ICI has produced many high-quality, practical, and effective resources for oncology care providers and patients including patient coverage and cessation activities.

Survivorship Compendium

The Survivorship Care Compendium has been developed to serve as a repository of tools and resources to enable oncology providers implement or improve survivorship care within their practices. The compendium serves as an accompaniment to the educational opportunities and clinical-guidance ICIoffers on survivorship care. Although ICI endorses the National Coalition for Cancer Survivorship definition of a cancer survivor as starting at the point of diagnosis, the focus of this compendium is on individuals who have completed curative treatment or who have transitioned to maintenance or prophylactic therapy.

Vaccination for Prevention

ICI’s Efforts in Vaccination

ASCO is working on two main vaccination initiatives:

  • Raising awareness about the importance of vaccines in cancer prevention.
  • Implementing concrete strategies to address barriers to vaccine access and acceptance.

FDA-Approved Vaccines

Currently, there are two types of FDA-approved vaccines to prevent cancer: Vaccines against human papillomavirus (HPV) and vaccines against the Hepatitis B virus (HBV).

Human Papillomavirus (HPV)

Cervical cancer is the fourth most common cancer in women worldwide, and human papillomavirus is the cause of approximately 99.7% of cervical cancer cases. In 2012, there were over 260,000 deaths from cervical cancer worldwide, accounting for 7.5% of female cancer deaths. Additionally, HPV is the leading cause of oropharyngeal cancers. HPV is also the cause of 91% of anal cancers, 75% of vaginal cancers, 69% of vulvar cancers, and 63% of penile cancers.

HPV cancer prevention logo We're In!

Hepatitis B (HBV)

Chronic infection with hepatitis is responsible for 80% of all primary liver cancers worldwide, causing more than 500,000 deaths annually and making it the third leading cause of cancer mortality. The most common risk factor for liver cancer is HBV. Those with chronic HBV infection are 100 times more likely to develop the disease, compared to  uninfected people. Since the rate of chronic HBV infections is on the rise in Kenya, there is a growing incidence of primary liver cancer. Liver cancer has become one of the fastest growing cancers in Kenya.

Familial Risk Assessment & Management

ICI’s Efforts in Cancer Genetics

Approximately 5-10% of newly diagnosed cancers are genetically inherited. ICI has a broad set of initiatives designed to improve the quality of preventive and therapeutic care for patients with cancer, and family members who are at hereditary risk for cancer.

ICI’s goals in cancer genetics include:

  • Developing an oncology workforce capable of identifying and caring for people at increased genetic risk of cancer
  • Advancing and expand access to care provided to patients and families affected by hereditary cancer syndromes

Continued Initiatives to Improve Care for Patients

ICI’s initiatives in cancer genetics began recently. These initiatives have resulted in important educational offerings and policy recommendations to improve the quality of both preventive and therapeutic oncologic care for patients with cancer and their families at hereditary risk for cancer. Several trends expected over the coming years will require continued ICI initiatives in this area. These trends include increased protections of genetic privacy, decreasing costs of molecular genetic testing technologies, the emergence of low penetrance and pharmacogenetic risk markers, and the increasing demand for cancer genetic services.

Currently, ICI is focused on the following areas:

  • Provider Education: development of education initiatives to increase oncologists’ core knowledge about:
    • Hereditary cancer susceptibility syndromes
    • Methods of cancer risk assessment and risk management
    • Awareness of novel targets and ideas (i.e. pharmacogenetics)
  • Physician Tools and Resources: to support oncologists in integrating hereditary cancer risk assessment into clinical practice and to ensure that adequate reimbursement is available for these services
  • QOPI Measures: development and revision of family history and genetic counseling measures for integration into QOPI


Visit us on social networks:

Visit us on social networks:

International Cancer Institute
P.O. Box 8088 – 30100
Eldoret, Kenya

+254 718 473 446

Call us now with any concerns or questions, we will reply swiftly and provide you with the help you need.

Copyright by International Cancer Institute 2018. All rights reserved.